Equities

Phathom Pharmaceuticals Inc

PHAT:NSQ

Phathom Pharmaceuticals Inc

Actions
  • Price (USD)9.34
  • Today's Change-0.11 / -1.16%
  • Shares traded1.22m
  • 1 Year change+33.62%
  • Beta0.6176
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Phathom Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 28.00 and a low estimate of 18.00. The median estimate represents a 199.79% increase from the last price of 9.34.
High199.8%28.00
Med199.8%28.00
Low92.7%18.00

Earnings history & estimates in USD

On Nov 07, 2024, Phathom Pharmaceuticals Inc reported 3rd quarter 2024 losses of -1.32 per share. This result exceeded the -1.50 consensus loss of the 6 analysts covering the company and under-performed last year's 3rd quarter results by 73.68%.
The next earnings announcement is expected on Mar 05, 2025.
Average growth rate-19.88%
Phathom Pharmaceuticals Inc reported annual 2023 losses of -3.93 per share on Mar 07, 2024.
Average growth rate+18.70%
More ▼

Revenue history & estimates in USD

Phathom Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 16.35m. This bettered the 12.61m consensus of the 7 analysts covering the company.
Average growth rate+195.56%
Phathom Pharmaceuticals, Inc. had revenues for the full year 2023 of 682.00k.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.